Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to site content Skip directly to page options
CDC Home

BOTUSA (Botswana-USA Partnership)

HIV Prevention Research (HPR)

 

TDF Recruiting

CDC, in partnership with the Botswana Ministry of Health, conducted the ground-breaking TDF2 study to determine if a daily oral dose of antiretroviral drugs could reduce the risk of HIV transmission among heterosexual men and women. Providing antiretroviral drugs to uninfected individuals prior to HIV exposure is called pre-exposure prophylaxis, or PrEP.

TDF2 study findings, announced in July 2011, provide the first evidence that PrEP can reduce risk of HIV infection among heterosexuals. CDC is assessing data from this Botswana-based study and other PrEP research to develop interim guidance for use of PrEP in heterosexual populations.

To learn more:

 

 
Contact Us:
  • Centers for Disease Control and Prevention
    1600 Clifton Rd
    Atlanta, GA 30333
  • 800-CDC-INFO
    (800-232-4636)
    TTY: (888) 232-6348
  • Contact CDC–INFO
  • Kathleen E. Toomey, MD, MPH
    Director
    BOTUSA
    Plot 14818 Lebatlane Road
    Phase One
    P.O. Box 90
    Gaborone, Botswana

U.S. President's Emergency Plan for AIDS Relief
U.S. President's Emergency Plan for AIDS Relief

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO
A-Z Index
  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
  27. #